C4 Therapeutics stake updated by Morgan Stanley

Morgan Stanley and its affiliates reported updated ownership of C4 Therapeutics, Inc. common stock on Schedule 13G/A (Amendment No. 3).

Rhea-AI Filing Summary

Morgan Stanley and its affiliates reported updated ownership of C4 Therapeutics, Inc. common stock on Schedule 13G/A (Amendment No. 3). Morgan Stanley reported beneficial ownership of 8,862,002 shares of C4 Therapeutics common stock, representing 8.0% of the outstanding class.

Morgan Stanley Capital Services LLC reported beneficial ownership of 8,718,000 shares, or 7.9%, all with shared voting and dispositive power. Morgan Stanley & Co. LLC reported 134,047 shares, or 0.1%, and stated that it has ceased to be the beneficial owner of more than five percent of this class of securities.

Key Figures

Morgan Stanley shares beneficially owned: 8,862,002 shares Morgan Stanley ownership percentage: 8.0% Morgan Stanley Capital Services LLC shares: 8,718,000 shares +3 more

6 metrics

Morgan Stanley shares beneficially owned 8,862,002 shares C4 Therapeutics common stock beneficially owned by Morgan Stanley, representing 8.0% of the class

Morgan Stanley ownership percentage 8.0% Percent of C4 Therapeutics common stock class reported as beneficially owned by Morgan Stanley

Morgan Stanley Capital Services LLC shares 8,718,000 shares C4 Therapeutics common stock beneficially owned by Morgan Stanley Capital Services LLC, 7.9% of the class

Morgan Stanley Capital Services LLC ownership 7.9% Percent of C4 Therapeutics common stock class held by Morgan Stanley Capital Services LLC

Morgan Stanley & Co. LLC shares 134,047 shares C4 Therapeutics common stock beneficially owned by Morgan Stanley & Co. LLC, 0.1% of the class

Morgan Stanley & Co. LLC ownership 0.1% Percent of C4 Therapeutics common stock class held by Morgan Stanley & Co. LLC

Key Terms

beneficially owned, shared voting power, shared dispositive power, dispositive power, +1 more

5 terms

beneficially owned financial

"this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 8,860,219.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 8,862,002.00"

dispositive power financial

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 8,718,000.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of C4 Therapeutics (CCCC) is owned by Morgan Stanley?

Morgan Stanley reported beneficial ownership of 8,862,002 C4 Therapeutics common shares, representing 8.0% of the class. This ownership is held with shared voting and dispositive power through specified Morgan Stanley reporting units.

How many C4 Therapeutics (CCCC) shares does Morgan Stanley Capital Services LLC hold?

Morgan Stanley Capital Services LLC reported beneficial ownership of 8,718,000 C4 Therapeutics common shares, equal to 7.9% of the class. All of these shares are listed with shared voting power and shared dispositive power.

What is Morgan Stanley & Co. LLC’s current position in C4 Therapeutics (CCCC)?

Morgan Stanley & Co. LLC reported beneficial ownership of 134,047 C4 Therapeutics shares, or 0.1% of the class. It also noted that it has ceased to be the beneficial owner of more than five percent of this class.

What does Schedule 13G/A Amendment No. 3 disclose about C4 Therapeutics (CCCC)?

Schedule 13G/A Amendment No. 3 discloses updated beneficial ownership of C4 Therapeutics common stock by Morgan Stanley and certain subsidiaries, including total shares held, percentage of the class, and the nature of voting and dispositive powers.

Who signed the C4 Therapeutics (CCCC) Schedule 13G/A on behalf of Morgan Stanley?

The filing was signed by Claire Gordon as Authorized Signatory for Morgan Stanley, Morgan Stanley Capital Services LLC, and Morgan Stanley & Co. LLC, each dated 08/12/2026, confirming the reported ownership information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 04:42 PM Accepted by SEC EDGAR 08/12/2026 - 04:41 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

C4 Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

12529R107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 12529R107

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,860,219.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,862,002.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,862,002.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.0 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP Number(s): 12529R107

1

Names of Reporting Persons

Morgan Stanley Capital Services LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,718,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,718,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,718,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.9 %

12

Type of Reporting Person (See Instructions)

BD, CO

SCHEDULE 13G

CUSIP Number(s): 12529R107

1

Names of Reporting Persons

Morgan Stanley & Co. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 134,047.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 134,047.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

134,047.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

BD, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley & Co. LLC has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: C4 Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Capital Services LLC 3: Morgan Stanley & Co. LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036 ;3: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware 3: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 12529R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 8.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/12/2026

Morgan Stanley Capital Services LLC

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley Capital Services LLC
Date:	08/12/2026

Morgan Stanley & Co. LLC

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley & Co. LLC
Date:	08/12/2026

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).